Latest Cardiome Pharma Corp (CRME) Headlines
Cardiome Closes C$30 Million Primary And Secondary Common Share Offering
PR Newswire - Tue Mar 11, 8:45AM CDT
NASDAQ: CRME TSX: COM
Shares of CRME Up 55.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Mar 10, 9:09AM CDT
SmarTrend identified an Uptrend for Cardiome Pharma (NASDAQ:CRME) on November 21st, 2013 at $5.60. In approximately 4 months, Cardiome Pharma has returned 55.00% as of today's recent price of $8.68.
Nasdaq stocks posting largest percentage decreases
AP - Thu Mar 06, 5:07PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
OncoGenex Pharmaceuticals (OGXI) Soars: Stock Up 6.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 7:51AM CST
OncoGenex Pharmaceuticals, Inc. was a big mover last session, as its shares rose nearly 7% on the day.
Cardiome Pharma Has Returned 73.0% Since SmarTrend Recommendation (CRME)
Comtex SmarTrend(R) - Fri Feb 28, 4:44PM CST
SmarTrend identified an Uptrend for Cardiome Pharma (NASDAQ:CRME) on November 21st, 2013 at $5.60. In approximately 3 months, Cardiome Pharma has returned 73.04% as of today's recent price of $9.69.
Avanir Pharmaceuticals (AVNR) Jumps: Stock Moves 11.7% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 8:46AM CST
Avanir Pharmaceuticals was a big mover last session, with shares rising nearly 12%.
Can The Uptrend Continue for CARDIOME (CRME)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 9:13AM CST
Can The Uptrend Continue for CARDIOME (CRME)?
59.6% Return Seen to Date on SmarTrend Cardiome Pharma Call (CRME)
Comtex SmarTrend(R) - Fri Feb 21, 11:01AM CST
SmarTrend identified an Uptrend for Cardiome Pharma (NASDAQ:CRME) on November 21st, 2013 at $5.60. In approximately 3 months, Cardiome Pharma has returned 59.63% as of today's recent price of $8.94.
Cardiome Pharma enters into CAD30m combined bought deal offering with group of underwriters
M2 - Fri Feb 21, 5:53AM CST
Biopharmaceutical company Cardiome Pharma (NASDAQ:CRME) (TSX:COM) and CarCor Investment Holdings LLC Thursday jointly announced the execution of an agreement with a group of underwriters for a combined bought deal offering of CAD30m.
Cardiome Announces C$30 Million Primary and Secondary Common Share Offering
PR Newswire - Thu Feb 20, 6:33AM CST
Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) ("Cardiome") and CarCor Investment Holdings LLC ("CarCor"), the shareholder from which Cardiome purchased Correvio LLC, are pleased to announce that they have entered into an agreement with a group of underwriters (the "Underwriters") for the sale, on a bought deal basis, of 1,500,000 common shares from Cardiome for gross proceeds of C$15 million (the "Primary Offering") and 1,500,000 common shares in a secondary offering from Carcor for gross proceeds of C$15 million (the "Secondary Offering") both at C$10.00 per common share, for a combined offering of C$30 million (collectively, the "Offering").
Cardiome Announces Update in Commercialization Partnership for BRINAVESS(TM) in Select European Markets
PR Newswire Europe - Wed Feb 19, 8:44AM CST
VANCOUVER, February 19, 2014 /PRNewswire/ --
Cardiome Announces Update in Commercialization Partnership for BRINAVESS™ in Select European Markets
PR Newswire - Wed Feb 19, 7:45AM CST
NASDAQ: CRME TSX: COM
Cardiome Enters BRINAVESS Distribution Agreement With Nomeco A/S in Denmark
PR Newswire Europe - Tue Feb 18, 6:51AM CST
VANCOUVER, British Columbia, February 18, 2014 /PRNewswire/ --
Cardiome Announces At-The-Market Offering
CNW Group - Tue Feb 18, 6:45AM CST
NASDAQ: CRME TSX: COM
Cardiome Closes C$30 Million Primary And Secondary Common Share Offering
PR Newswire - Tue Mar 11, 8:45AM CDT
NASDAQ: CRME TSX: COM
Shares of CRME Up 55.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Mar 10, 9:09AM CDT
SmarTrend identified an Uptrend for Cardiome Pharma (NASDAQ:CRME) on November 21st, 2013 at $5.60. In approximately 4 months, Cardiome Pharma has returned 55.00% as of today's recent price of $8.68.
Nasdaq stocks posting largest percentage decreases
AP - Thu Mar 06, 5:07PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
OncoGenex Pharmaceuticals (OGXI) Soars: Stock Up 6.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 7:51AM CST
OncoGenex Pharmaceuticals, Inc. was a big mover last session, as its shares rose nearly 7% on the day.
Cardiome Pharma Has Returned 73.0% Since SmarTrend Recommendation (CRME)
Comtex SmarTrend(R) - Fri Feb 28, 4:44PM CST
SmarTrend identified an Uptrend for Cardiome Pharma (NASDAQ:CRME) on November 21st, 2013 at $5.60. In approximately 3 months, Cardiome Pharma has returned 73.04% as of today's recent price of $9.69.
Avanir Pharmaceuticals (AVNR) Jumps: Stock Moves 11.7% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 8:46AM CST
Avanir Pharmaceuticals was a big mover last session, with shares rising nearly 12%.
Can The Uptrend Continue for CARDIOME (CRME)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 9:13AM CST
Can The Uptrend Continue for CARDIOME (CRME)?
59.6% Return Seen to Date on SmarTrend Cardiome Pharma Call (CRME)
Comtex SmarTrend(R) - Fri Feb 21, 11:01AM CST
SmarTrend identified an Uptrend for Cardiome Pharma (NASDAQ:CRME) on November 21st, 2013 at $5.60. In approximately 3 months, Cardiome Pharma has returned 59.63% as of today's recent price of $8.94.
Cardiome Pharma enters into CAD30m combined bought deal offering with group of underwriters
M2 - Fri Feb 21, 5:53AM CST
Biopharmaceutical company Cardiome Pharma (NASDAQ:CRME) (TSX:COM) and CarCor Investment Holdings LLC Thursday jointly announced the execution of an agreement with a group of underwriters for a combined bought deal offering of CAD30m.
Cardiome Announces C$30 Million Primary and Secondary Common Share Offering
PR Newswire - Thu Feb 20, 6:33AM CST
Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) ("Cardiome") and CarCor Investment Holdings LLC ("CarCor"), the shareholder from which Cardiome purchased Correvio LLC, are pleased to announce that they have entered into an agreement with a group of underwriters (the "Underwriters") for the sale, on a bought deal basis, of 1,500,000 common shares from Cardiome for gross proceeds of C$15 million (the "Primary Offering") and 1,500,000 common shares in a secondary offering from Carcor for gross proceeds of C$15 million (the "Secondary Offering") both at C$10.00 per common share, for a combined offering of C$30 million (collectively, the "Offering").
Cardiome Announces Update in Commercialization Partnership for BRINAVESS(TM) in Select European Markets
PR Newswire Europe - Wed Feb 19, 8:44AM CST
VANCOUVER, February 19, 2014 /PRNewswire/ --
Cardiome Announces Update in Commercialization Partnership for BRINAVESS™ in Select European Markets
PR Newswire - Wed Feb 19, 7:45AM CST
NASDAQ: CRME TSX: COM
Cardiome Enters BRINAVESS Distribution Agreement With Nomeco A/S in Denmark
PR Newswire Europe - Tue Feb 18, 6:51AM CST
VANCOUVER, British Columbia, February 18, 2014 /PRNewswire/ --
Cardiome Announces At-The-Market Offering
CNW Group - Tue Feb 18, 6:45AM CST
NASDAQ: CRME TSX: COM
